Robyn M. Hunter
Net Worth
Last updated:
What is Robyn M. Hunter net worth?
The estimated net worth of Ms. Robyn M. Hunter is at least $10,248,420 as of 21 Sep 2021. She owns shares worth $1,605,995 as insider, has earned $478,885 from insider trading and has received compensation worth at least $8,163,540 in Fortress Biotech, Inc. and Fortress Biotech, Inc..
What is the salary of Robyn M. Hunter?
Ms. Robyn M. Hunter salary is $583,110 per year as Chief Financial Officer, Treasurer & Corporation Sec. in Fortress Biotech, Inc.. She also receives $583,110 as Chief Financial Officer, Treasurer & Corporation Sec. in Fortress Biotech, Inc..
How old is Robyn M. Hunter?
Ms. Robyn M. Hunter is 63 years old, born in 1962.
What stocks does Robyn M. Hunter currently own?
As insider, Ms. Robyn M. Hunter owns shares in 2 companies:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | Chief Financial Officer, Treasurer & Corporation Sec. | 163,877 | $2.23 | $365,446 |
| Fortress Biotech, Inc. (FBIOP) | Chief Financial Officer, Treasurer & Corporation Sec. | 163,877 | $7.57 | $1,240,549 |
What does Fortress Biotech, Inc. do?
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
What does Fortress Biotech, Inc. do?
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
Robyn M. Hunter insider trading
Fortress Biotech, Inc.
Ms. Robyn M. Hunter has made 3 insider trades between 2018-2021, according to the Form 4 filled with the SEC. Most recently she sold 28,292 units of FBIO stock worth $88,554 on 21 Sep 2021.
The largest trade she's ever made was exercising 28,450 units of FBIO stock on 22 Sep 2020. As of 21 Sep 2021 she still owns at least 163,877 units of FBIO stock.
Fortress Biotech, Inc.
Ms. Robyn M. Hunter has made 3 insider trades between 2018-2021, according to the Form 4 filled with the SEC. Most recently she sold 28,292 units of FBIOP stock worth $88,554 on 21 Sep 2021.
The largest trade she's ever made was exercising 28,450 units of FBIOP stock on 22 Sep 2020. As of 21 Sep 2021 she still owns at least 163,877 units of FBIOP stock.
Fortress Biotech key executives
Fortress Biotech, Inc. executives and other stock owners filed with the SEC:
- Dr. George C. Avgerinos (71) Senior Vice President of Biologics Operations
- Dr. Lindsay Allan Rosenwald (70) Executive Chairman, Pres & Chief Executive Officer
- Mr. Michael S. Weiss Esq. (59) Vice Chairman & Executive Vice Chairman of Strategic Devel.
- Ms. Robyn M. Hunter (63) Chief Financial Officer, Treasurer & Corporation Sec.